BioCentury
ARTICLE | Clinical News

Eroxon: Phase III started

July 13, 2015 7:00 AM UTC

Futura began a double-blind, placebo-controlled, crossover, European Phase III trial to evaluate 4 doses of 300 mg topical MED2002 over 4 weeks in 192 patients. ...